

Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval for generic Plavix[®] tablets

Mumbai, May 18, 2012: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for its generic version of Plavix[®], Clopidogrel Tablets USP, 75 mg.

These generic Clopidogrel Tablets USP, 75 mg. are therapeutic equivalents of Plavix[®] tablets from Sanofi-Aventis. Clopidogrel Tablets have annual sale of approximately \$ 6.7 billion in the US.

Clopidogrel Tablets USP, are indicated for Acute Coronary Syndrome & recent MI, recent stroke, or established peripheral arterial disease.

Plavix[®] is a registered trademark of Sanofi-Aventis U.S. LLC (Sanofi)

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, gastroenterology, ophthalmology and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail mira.desai@sunpharma.com